Suppr超能文献

罗得西亚锥虫分离株的毒力差异并不影响抗锥虫药物在小鼠模型中的治疗效果。

Differential virulence of Trypanosoma brucei rhodesiense isolates does not influence the outcome of treatment with anti-trypanosomal drugs in the mouse model.

机构信息

Biotechnology Research Institute, Kenya Agricultural and Livestock Research Organization, Kikuyu, Kenya.

KAG EAST University, Nairobi, Kenya.

出版信息

PLoS One. 2020 Nov 5;15(11):e0229060. doi: 10.1371/journal.pone.0229060. eCollection 2020.

Abstract

We assessed the virulence and anti-trypanosomal drug sensitivity patterns of Trypanosoma brucei rhodesiense (Tbr) isolates in the Kenya Agricultural and Livestock Research Organization-Biotechnology Research Institute (KALRO-BioRI) cryobank. Specifically, the study focused on Tbr clones originally isolated from the western Kenya/eastern Uganda focus of human African Trypanosomiasis (HAT). Twelve (12) Tbr clones were assessed for virulence using groups(n = 10) of Swiss White Mice monitored for 60 days post infection (dpi). Based on survival time, four classes of virulence were identified: (a) very-acute: 0-15, (b) acute: 16-30, (c) sub-acute: 31-45 and (d) chronic: 46-60 dpi. Other virulence biomarkers identified included: pre-patent period (pp), parasitaemia progression, packed cell volume (PCV) and body weight changes. The test Tbr clones together with KALRO-BioRi reference drug-resistant and drug sensitive isolates were then tested for sensitivity to melarsoprol (mel B), pentamidine, diminazene aceturate and suramin, using mice groups (n = 5) treated with single doses of each drug at 24 hours post infection. Our results showed that the clones were distributed among four classes of virulence as follows: 3/12 (very-acute), 3/12 (acute), 2/12 (sub-acute) and 4/12 (chronic) isolates. Differences in survivorship, parasitaemia progression and PCV were significant (P<0.001) and correlated. The isolate considered to be drug resistant at KALRO-BioRI, KETRI 2538, was confirmed to be resistant to melarsoprol, pentamidine and diminazene aceturate but it was not resistant to suramin. A cure rate of at least 80% was achieved for all test isolates with melarsoprol (1mg/Kg and 20 mg/kg), pentamidine (5 and 20 mg/kg), diminazene aceturate (5 mg/kg) and suramin (5 mg/kg) indicating that the isolates were not resistant to any of the drugs despite the differences in virulence. This study provides evidence of variations in virulence of Tbr clones from a single HAT focus and confirms that this variations is not a significant determinant of isolate sensitivity to anti-trypanosomal drugs.

摘要

我们评估了肯尼亚农业和畜牧业研究组织生物技术研究所(KALRO-BioRI)低温库中布氏冈比亚锥虫(Tbr)分离株的毒力和抗疟药物敏感性模式。具体来说,该研究集中在最初从肯尼亚西部/乌干达东部人类非洲锥虫病(HAT)焦点分离的 Tbr 克隆上。使用感染后 60 天(dpi)监测的 10 组瑞士白老鼠评估了 12 个 Tbr 克隆的毒力。根据存活时间,确定了四类毒力:(a)非常急性:0-15,(b)急性:16-30,(c)亚急性:31-45,(d)慢性:46-60 dpi。确定的其他毒力生物标志物包括:潜伏前期(pp)、寄生虫血症进展、红细胞压积(PCV)和体重变化。然后,使用在感染后 24 小时用每种药物单次剂量治疗的 5 组老鼠,测试了测试 Tbr 克隆以及 KALRO-BioRi 参考耐药和敏感分离株对米乐砷(mel B)、戊烷脒、二脒替嗪乙酰脲和苏拉明的敏感性。我们的结果表明,克隆分布在以下四类毒力中:3/12(非常急性)、3/12(急性)、2/12(亚急性)和 4/12(慢性)分离株。存活率、寄生虫血症进展和 PCV 的差异具有统计学意义(P<0.001)且相关。在 KALRO-BioRI 被认为是耐药的分离株 KETRI 2538 被证实对米乐砷、戊烷脒和二脒替嗪乙酰脲耐药,但对苏拉明不耐药。所有测试分离株用米乐砷(1mg/Kg 和 20mg/kg)、戊烷脒(5 和 20mg/kg)、二脒替嗪乙酰脲(5mg/kg)和苏拉明(5mg/kg)的治愈率至少为 80%,表明尽管毒力存在差异,但分离株对任何药物均无耐药性。这项研究提供了来自单一 HAT 焦点的 Tbr 克隆毒力变化的证据,并证实这种变化不是分离株对抗锥虫药物敏感性的重要决定因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45ae/7643984/58e44e0ca098/pone.0229060.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验